🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

953 results for “injection” Clear

  1. Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  3. Imnovid 1 mg hard capsules, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, Imnovid 4 mg hard capsules, Dexamethason CF 20 mg/ml, injectievloeistof, CC-92480, Dexamethason 4 mg JENAPHARM®, Imnovid 2 mg hard capsules, DEXAMETHASONE, Dexamethason 4 mg GALEN®, CC-92480, Imnovid 3 mg hard capsules, CC-92480, CC-92480, VELCADE 1 mg powder for solution for injection

    Celgene Europe Limited

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  4. Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Pomalidomide, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, VELCADE 3.5 mg powder for solution for injection, Imnovid 3 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Privigen 100 mg/ml solution for infusion, teclistamab, Pomalidomide, Dexamethason 4 mg JENAPHARM®, Fortecortin® 2 mg Tabletten, teclistamab, Pomalidomide, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infu

    Janssen-Cilag International N.V.

    Relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  5. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Lacuna Pharma Pty Ltd

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  6. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie

    Disc Medicine

    Delirium

    phase 3 small molecule active

    1 trial

  8. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  9. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  10. Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

    Regeneron UK Limited

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  11. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  12. Ivonescimab Injection

    Summit Therapeutics

    Non-Small Cell Lung Cancer

    phase 3 mab active

    2 trials

  13. JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  14. Jivi 500 IU powder and solvent for solution for injection, Jivi 1000 IU powder and solvent for solution for injection

    Bayer AG

    Severe hemophilia A (<1% FVIII:C)

    phase 3 small molecule active

    1 trial

  15. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  16. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Livmoniplimab, Carboplatin 10 mg/ml Intravenous Infusion, Pemetrexed medac 500 mg powder for concentrate for solution for infusion, Cisplatin 1mg/ml Injection BP, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  18. Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  19. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe., COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    Familial Mediterranean Fever (FMF)

    phase 3 small molecule active

    1 trial

  20. Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe., Privigen 100 mg/ml solution for infusion

    Pari Pharma GmbH

    Kawasaki disease

    phase 3 small molecule active

    1 trial

  21. Kyprolis 60 mg powder for solution for infusion, Kyprolis 30 mg powder for solution for infusion, DARZALEX 1800 mg solution for injection, ENDOXAN omhulde tablet, omhulde tabletten, 50 mg, Cesnicabtagene autoleucel, Kyprolis 10 mg powder for solution for infusion, Dexamethason Teva 4 mg, tabletten, Bortezomib Accord 3.5 mg powder for solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Dexamethason Activase 2 mg tabletten, Pomalidomide Accord 4 mg hard capsules, Emplic

    Disc Medicine

    relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  22. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  23. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  24. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources